Ipamorelin vs Sermorelin: Which GH Peptide Is Right for Your Research?

Ipamorelin is a selective growth hormone releasing peptide that binds to the ghrelin receptor (GHS-R) in the pituitary gland. Its key advantage is selectivity — it stimulates GH release without significantly raising cortisol, prolactin, or ACTH levels, unlike older GHRPs like GHRP-6.

This clean profile makes ipamorelin popular in research focused on GH optimization with minimal hormonal disruption.

Sermorelin is a truncated analog of natural GHRH (growth hormone releasing hormone), containing the first 29 amino acids. It binds to GHRH receptors on the pituitary, stimulating GH production and release in a pattern that mimics the body's natural pulsatile rhythm.

Sermorelin was FDA-approved for pediatric GH deficiency diagnosis, giving it one of the longest clinical track records among GH peptides.

Mechanism: Ipamorelin works via the ghrelin pathway, while sermorelin works via the GHRH pathway. These are distinct signaling routes, which is why they are often stacked.

Potency: Ipamorelin typically produces a stronger, more consistent GH pulse per dose. Sermorelin's effect can be blunted if somatostatin (GH-inhibiting hormone) is elevated.

Hunger: Ipamorelin causes minimal appetite increase compared to other ghrelin mimetics. Sermorelin has no significant effect on appetite.

Regulatory status: Sermorelin has more clinical data and was previously FDA-approved, giving it an edge in research credibility.

For clean, selective GH stimulation with minimal side effects, ipamorelin is excellent. For a well-studied compound that closely mimics natural GH signaling, sermorelin is a strong choice. Many researchers stack both to activate complementary pathways for amplified GH release.

Ensure your peptides are third-party tested. Ascension Peptides carries both ipamorelin and sermorelin with verified purity for research applications.